Behind the scenes at Généthon, researchers are reminding the public that breakthroughs in gene therapy depend on sustained support — without donations, they say, miracles in the lab simply won’t happen.
The message came during a recent visit to the French research institute, where scientists emphasized that progress in treating rare genetic diseases relies heavily on philanthropic funding. Généthon, a pioneer in the development of gene therapies for conditions like Duchenne muscular dystrophy and certain immune deficiencies, has made notable advances in recent years, but researchers stress that continued investment is essential to maintain momentum.
“Without donations, we won’t be able to turn scientific promise into real treatments for patients,” one researcher stated during the tour. The institute, which operates as a nonprofit, depends on contributions from individuals, foundations, and partnerships to fund its preclinical and clinical research programs.
Généthon has played a key role in advancing adeno-associated virus (AAV)-based therapies, some of which have led to approved treatments in Europe and the United States. Its work has helped lay the foundation for therapies that address the root genetic causes of diseases rather than just managing symptoms.
The visit highlighted not only the scientific work underway but likewise the human side of research — the teams working long hours in laboratories, the families affected by rare diseases who hope for breakthroughs, and the ongoing need for public engagement and support.
Experts note that gene therapy remains a costly and complex field, with manufacturing, regulatory hurdles, and long-term follow-up adding to the challenges. Institutions like Généthon argue that diversified funding sources are critical to sustaining innovation over the long term.
While the institute has celebrated several milestones, including the approval of gene therapies derived from its research, leaders say the next generation of treatments — particularly for more complex or prevalent conditions — will require even greater resources.
For patients and families living with rare genetic disorders, the message is clear: scientific progress is possible, but it depends on continued commitment from the broader community. As one scientist put it, “The miracles people hope for don’t happen in a vacuum. They happen because people choose to support the work that makes them possible.”
